ATE448225T1 - Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten - Google Patents

Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten

Info

Publication number
ATE448225T1
ATE448225T1 AT03793791T AT03793791T ATE448225T1 AT E448225 T1 ATE448225 T1 AT E448225T1 AT 03793791 T AT03793791 T AT 03793791T AT 03793791 T AT03793791 T AT 03793791T AT E448225 T1 ATE448225 T1 AT E448225T1
Authority
AT
Austria
Prior art keywords
aza
alpha7
nachr agonists
bicycloalkyl
ether
Prior art date
Application number
AT03793791T
Other languages
English (en)
Inventor
Dominik Feuerbach
Konstanze Hurth
Timothy John Ritchie
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9943515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE448225(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE448225T1 publication Critical patent/ATE448225T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03793791T 2002-09-04 2003-09-03 Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten ATE448225T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220581A GB0220581D0 (en) 2002-09-04 2002-09-04 Organic Compound
PCT/EP2003/009772 WO2004022556A1 (en) 2002-09-04 2003-09-03 Aza-bicycloalkyl ethers and their use as alpha7-nachr agonist

Publications (1)

Publication Number Publication Date
ATE448225T1 true ATE448225T1 (de) 2009-11-15

Family

ID=9943515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03793791T ATE448225T1 (de) 2002-09-04 2003-09-03 Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten

Country Status (25)

Country Link
US (8) US20060167002A1 (de)
EP (3) EP2308876A1 (de)
JP (2) JP4348422B2 (de)
KR (2) KR20070058027A (de)
CN (1) CN1325493C (de)
AT (1) ATE448225T1 (de)
AU (1) AU2003260486C1 (de)
BR (2) BRPI0314325B8 (de)
CA (1) CA2495685C (de)
CY (1) CY1109765T1 (de)
DE (1) DE60330015D1 (de)
DK (1) DK1537104T3 (de)
EC (1) ECSP055621A (de)
ES (1) ES2336099T3 (de)
GB (1) GB0220581D0 (de)
IL (2) IL166918A (de)
MX (1) MXPA05002546A (de)
NO (1) NO331556B1 (de)
NZ (1) NZ538534A (de)
PL (1) PL209425B1 (de)
PT (1) PT1537104E (de)
RU (1) RU2352569C2 (de)
SI (1) SI1537104T1 (de)
WO (1) WO2004022556A1 (de)
ZA (1) ZA200500816B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6262265A (ja) * 1985-09-13 1987-03-18 Hitachi Ltd 復水器自動検査補修システム
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
DE602004031124D1 (de) 2003-08-13 2011-03-03 Neurosearch As Neue chinuklidinderivative und deren pharmazeutische verwendung
US20050137398A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US20050137203A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
EP1824848A1 (de) * 2004-12-10 2007-08-29 Abbott Laboratories Mit einem kondensierten bicycloheterocyclus substituierte chinuclidinderivate
US20050245531A1 (en) * 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7309699B2 (en) 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
AU2005286648A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CA2580857A1 (en) 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7829712B2 (en) * 2004-09-20 2010-11-09 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
AU2006343359A1 (en) 2005-06-03 2007-11-15 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
GB0521508D0 (en) * 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) * 2005-12-16 2006-01-25 Novartis Ag Organic compounds
JP2009526777A (ja) 2006-02-14 2009-07-23 ノイロサーチ アクティーゼルスカブ ニコチン性アセチルコリン受容体作用薬としての３，９−ジアザビシクロ（３．３．１）ノナ−３−イル−アリールメタノン誘導体
US20100227869A1 (en) * 2006-02-16 2010-09-09 Dan Peters Enantiopure quinuclidinyloxy pyridazines and their use as nicotinic acetylcholine receptor ligands
ES2528797T3 (es) 2006-08-21 2015-02-12 Genentech, Inc. Compuestos de aza-benzotiofenilo y métodos de uso
RU2476220C2 (ru) * 2007-08-02 2013-02-27 Таргасепт, Инк. (2s,3r)-n-(2-((3-пиридинил)метил)-1-азабицикло[2.2.2]окт-3-ил)бензофуран-2-карбоксамид, новые солевые формы и способы их применения
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
MX2010014565A (es) 2008-07-01 2011-03-04 Genentech Inc Isoindolona y metodos de uso.
RU2509078C2 (ru) 2008-07-01 2014-03-10 Дженентек, Инк. Бициклические гетероциклы в качестве ингибиторов киназы мек
KR20180011888A (ko) 2008-11-19 2018-02-02 포럼 파마슈티칼즈 인크. (ｒ)-７-클로로-ｎ-(퀴누클리딘-３-일)벤조［ｂ］티오펜-２-카르복사미드 및 그 약학적으로 허용가능한 염을 이용한 인지 장애의 치료
PE20120324A1 (es) * 2009-05-11 2012-04-17 Envivo Pharmaceuticals Inc Combinacion que comprende (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y donezepilo como moduladora de trastornos cognitivos
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7
EP2488520B1 (de) 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Kondensierte azin-derivate zur behandlung von krankheiten die mit dem acetylcholin rezeptor in zusammenhang stehen
AR081402A1 (es) 2010-05-17 2012-08-29 Envivo Pharmaceuticals Inc Una forma cristalina de clorhidrato de (r)-7-cloro-n-(quinuclidin-3-il) benzo(b)tiofeno-2-carboxamida monohidrato
KR20140003580A (ko) * 2011-01-27 2014-01-09 노파르티스 아게 니코틴성 아세틸콜린 수용체 알파 7 활성화제의 용도
WO2012127393A1 (en) 2011-03-18 2012-09-27 Novartis Ag COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE
TWI589576B (zh) 2011-07-15 2017-07-01 諾華公司 氮雜－雙環二芳基醚之鹽類及製造彼等或其前驅物之方法
JP6162705B2 (ja) * 2011-10-20 2017-07-12 ノバルティス アーゲー アルファ７ニコチン性アセチルコリン受容体活性化剤による処置に対する応答性を予測するバイオマーカー
CA2872005A1 (en) 2012-05-08 2013-11-14 Forum Pharmaceuticals, Inc. Methods of maintaining, treating or improving cognitive function
KR102043309B1 (ko) * 2012-12-11 2019-11-11 노파르티스 아게 알파 7 니코틴성 아세틸콜린 수용체 활성화제 치료에 대한 반응성의 예측 바이오마커
EP2742940B1 (de) * 2012-12-13 2017-07-26 IP Gesellschaft für Management mbH (R)-3-(6-(4-methylphenyl)-pyridin-3-yloxy)-l-aza-bicyclo-[2.2.2]octane Fumarat zur einmal, zweimal oder dreimal täglichen Verabreichung
BR112015016992A8 (pt) * 2013-01-15 2018-01-23 Novartis Ag uso de agonistas do receptor alfa 7 nicotínico de acetilcolina
EP2945633B1 (de) * 2013-01-15 2021-06-30 Novartis AG Verwendung von alpha-7-nikotinischen acetylcholinrezeptoragonisten
US20150313884A1 (en) 2013-01-15 2015-11-05 Novartis Ag Use of alpha 7 nicotinic acetylcholine receptor agonists
CN105263492B (zh) * 2013-01-15 2018-04-10 诺华有限公司 α7烟碱型乙酰胆碱受体激动剂在治疗发作性睡病中的应用
GB201301626D0 (en) 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN116761604A (zh) * 2020-11-25 2023-09-15 万达制药公司 用α-7烟碱型乙酰胆碱受体激动剂治疗当众讲话焦虑
CA3199760A1 (en) * 2020-11-25 2022-06-02 Vanda Pharmaceuticals Inc. Treatment of public speaking anxiety with an alpha-7 nicotinic acetylcholine receptor agonist
KR20250005196A (ko) * 2022-05-05 2025-01-09 필립모리스 프로덕츠 에스.에이. 니코틴 아세틸콜린 수용체 리간드
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
WO2025188847A1 (en) * 2024-03-07 2025-09-12 The Texas A&M University System Method for treating epilepsy

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB809574A (en) 1956-01-26 1959-02-25 Gasaccumulator Svenska Ab Improvements in or relating to electrical signal light systems
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
BE759371A (fr) 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
DE2139107A1 (de) 1971-08-04 1973-02-15 Merck Patent Gmbh Heterocyclisch substituierte adenosinverbindungen
ZA848275B (en) 1983-12-28 1985-08-28 Degussa New piridine-2-ethers or pyridine-2-thioethers having a nitrogen-containing cycloaliphatic ring
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
ES2053451T3 (es) 1986-01-07 1994-08-01 Beecham Group Plc Un procedimiento para la preparacion de un compuesto que tiene propiedades farmacologicas utiles.
KR880007433A (ko) 1986-12-22 1988-08-27 메리 앤 터커 3-아릴옥시-3-치환된 프로판아민
EP0287356B1 (de) 1987-04-15 1996-01-24 Beecham Group Plc Am Brückenkopf substituierte Azabicyclenderivate
GB8718445D0 (en) 1987-08-04 1987-09-09 Wyeth John & Brother Ltd Pyridyl-ethers
CA1307790C (en) 1987-08-04 1992-09-22 Ian Anthony Cliffe Ethers
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3839385A1 (de) 1988-11-22 1990-05-23 Boehringer Ingelheim Kg Neue quinuclidine, ihre herstellung als arzneimittel und verfahren zu ihrer herstellung
GB8829079D0 (en) 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
CA2002182C (en) 1989-11-03 2000-06-13 Richard J. Wurtman Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use
DE4116582A1 (de) 1990-05-19 1991-11-21 Boehringer Ingelheim Kg Bicyclische 1-aza-cycloalkane
YU84791A (sh) 1990-05-19 1994-06-10 Boehringer Ingelheim Kg. Biciklicni 1-aza-cikloalkalni
US5589477A (en) 1990-08-31 1996-12-31 Nippon Shinyaku Company, Limited Pyrimidine derivatives and drugs
JP3087763B2 (ja) 1990-11-30 2000-09-11 三井化学株式会社 新規な複素環式化合物およびそれを含有する医薬組成物
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
JPH05310732A (ja) 1992-03-12 1993-11-22 Mitsubishi Kasei Corp シンノリン−３−カルボン酸誘導体
JPH06508377A (ja) 1992-04-10 1994-09-22 ゼネカ　リミテッド ヘテロ環式化合物
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
AU7394394A (en) 1992-10-13 1995-12-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-hydroxyquinuclidin-3-ylphenylquinolines as squalene synthase inhibitors
JPH06293768A (ja) 1993-02-12 1994-10-21 Sankyo Co Ltd イソオキサゾールオキシ誘導体
WO1994018201A1 (fr) 1993-02-12 1994-08-18 Sankyo Company, Limited Derive d'isoxazoleoxy
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5998404A (en) 1994-10-24 1999-12-07 Eli Lilly And Company Heterocyclic compounds and their use
JPH11512443A (ja) 1995-09-22 1999-10-26 ノボ ノルディスク アクティーゼルスカブ 新規な置換アザ環式またはアザ二環式化合物
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
JP2002500652A (ja) 1997-05-30 2002-01-08 ニューロサーアチ・アクティーゼルスカブ スピロ−キヌクリジン誘導体、その製造方法及びその使用方法
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6432975B1 (en) 1998-12-11 2002-08-13 Targacept, Inc. Pharmaceutical compositions and methods for use
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
ES2313900T3 (es) 1999-07-28 2009-03-16 The Board Of Trustees Of The Leland Stanford Junior University Nicotina en angiogenesis y vasculogenesis terapeutica.
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE9904176D0 (sv) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (sv) * 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
WO2001066546A1 (en) 2000-03-09 2001-09-13 Mitsubishi Pharma Corporation Spiro compounds, process for preparing the same and use thereof as drugs
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
JP4616971B2 (ja) 2000-07-18 2011-01-19 田辺三菱製薬株式会社 １−アザビシクロアルカン化合物およびその医薬用途
US6479510B2 (en) 2000-08-18 2002-11-12 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
GB0021885D0 (en) 2000-09-06 2000-10-18 Fujisawa Pharmaceutical Co New use
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
BR0213760A (pt) 2001-10-26 2004-10-19 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
DE10162375A1 (de) 2001-12-19 2003-07-10 Bayer Ag Bicyclische N-Aryl-amide
CA2475773A1 (en) 2002-02-20 2003-09-04 Pharmacia & Upjohn Company Azabicyclic compounds with alfa7 nicotinic acetylcholine receptor activity
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
AU2003250322B2 (en) * 2002-08-14 2010-01-21 Neurosearch A/S Novel quinuclidine derivatives and their use
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
MXPA05003317A (es) 2002-09-25 2005-07-05 Memory Pharm Corp Indazoles, benzotiazoles y benzoisotiazoles asi como preparacion y usos de los mismos.
WO2004039321A2 (en) 2002-10-29 2004-05-13 Miicro, Inc. Combinative nicotinic/d1 agonism therapy for the treatment of alzheimer’s disease
WO2004039366A1 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO2004039815A2 (en) 2002-11-01 2004-05-13 Pharmacia & Upjohn Company Llc Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
DK1562945T3 (da) 2002-11-11 2007-03-05 Neurosearch As Hidtil ukendte diazebicykliske biarylderivater
KR20050085535A (ko) 2002-12-11 2005-08-29 파마시아 앤드 업존 캄파니 엘엘씨 알파 7 니코틴성 아세틸콜린 수용체 아고니스트와 다른화합물의 조합물을 사용한 질환의 치료 방법
WO2004064836A2 (en) 2003-01-22 2004-08-05 Pharmacia & Upjohn Company Llc Treatment of diseases with alpha-7 nach receptor full agonists
WO2005013910A2 (en) 2003-08-07 2005-02-17 University Of South Florida Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors
JP4226981B2 (ja) 2003-09-24 2009-02-18 三井金属鉱業株式会社 プリント配線板の製造方法及びその製造方法で得られたプリント配線板
US20050137203A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-quinuclidinyl amino-substituted biaryl derivatives
US20050137398A1 (en) 2003-12-22 2005-06-23 Jianguo Ji 3-Quinuclidinyl heteroatom bridged biaryl derivatives
EP1824848A1 (de) 2004-12-10 2007-08-29 Abbott Laboratories Mit einem kondensierten bicycloheterocyclus substituierte chinuclidinderivate
US20050137204A1 (en) 2003-12-22 2005-06-23 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20070060588A1 (en) 2003-12-22 2007-03-15 Jianguo Ji Fused bicycloheterocycle substituted quinuclidine derivatives
US7655657B2 (en) 2003-12-22 2010-02-02 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7241773B2 (en) 2003-12-22 2007-07-10 Abbott Laboratories 3-quinuclidinyl heteroatom bridged biaryl derivatives
US7160876B2 (en) 2003-12-22 2007-01-09 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005063296A2 (en) 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
KR20070030196A (ko) 2004-04-13 2007-03-15 이카겐, 인코포레이티드 칼륨 이온 채널 조절제로서의 폴리시클릭 피리딘
JP2007538046A (ja) 2004-05-19 2007-12-27 ノイロサーチ アクティーゼルスカブ 新規なアザビシクロアリール誘導体
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
EP1802616B1 (de) 2004-10-15 2011-01-12 NeuroSearch A/S Neue azabizyklische arylderivate und medizinische verwendung damit
GB0424564D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
ATE481407T1 (de) 2005-02-16 2010-10-15 Neurosearch As Neue diazabicyclische arylderivate und medizinische verwendung dafür
EP1863485A2 (de) 2005-03-18 2007-12-12 Abbott Laboratories Alpha7-neuronaler nikotin-rezeptorligand und antipsychotische zusammensetzungen
WO2006113650A1 (en) 2005-04-18 2006-10-26 Khan Saeed R Design and synthesis of novel tubulin polymerization inhibitors: bonzoylphenyluria (bpu) sulfur analogs
FR2884822B1 (fr) 2005-04-22 2007-06-29 Aventis Pharma Sa Derives de triazines, leur preparation et leur application en therapeutique
GB0508314D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
MX2007016180A (es) 2005-06-14 2008-03-07 Schering Corp Inhibidores de aspartil proteasas.
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands

Also Published As

Publication number Publication date
US20170112814A1 (en) 2017-04-27
NO331556B1 (no) 2012-01-23
ECSP055621A (es) 2005-04-18
IL166918A (en) 2013-04-30
CA2495685A1 (en) 2004-03-18
WO2004022556A1 (en) 2004-03-18
EP2308876A1 (de) 2011-04-13
PT1537104E (pt) 2010-01-28
IL225002A (en) 2015-07-30
US20190083474A1 (en) 2019-03-21
DE60330015D1 (de) 2009-12-24
AU2003260486C1 (en) 2009-03-26
US8236803B2 (en) 2012-08-07
US9567343B2 (en) 2017-02-14
AU2003260486B2 (en) 2007-07-05
JP4348422B2 (ja) 2009-10-21
BRPI0314325B8 (pt) 2021-07-27
KR20050057126A (ko) 2005-06-16
KR20070058027A (ko) 2007-06-07
ES2336099T3 (es) 2010-04-08
BRPI0314325B1 (pt) 2018-04-17
HK1078868A1 (en) 2006-03-24
US20060167002A1 (en) 2006-07-27
SI1537104T1 (sl) 2010-03-31
MXPA05002546A (es) 2005-05-27
US20070249617A1 (en) 2007-10-25
NZ538534A (en) 2006-03-31
NO20051626L (no) 2005-05-27
US20180078536A1 (en) 2018-03-22
US20090054446A1 (en) 2009-02-26
PL209425B1 (pl) 2011-08-31
RU2352569C2 (ru) 2009-04-20
ZA200500816B (en) 2006-07-26
GB0220581D0 (en) 2002-10-09
JP5124714B2 (ja) 2013-01-23
CN1678611A (zh) 2005-10-05
JP2009143956A (ja) 2009-07-02
PL374013A1 (en) 2005-09-19
CA2495685C (en) 2012-11-06
RU2005109913A (ru) 2006-01-10
BR0314325A (pt) 2005-07-05
EP1537104A1 (de) 2005-06-08
KR100808324B1 (ko) 2008-02-27
EP1537104B1 (de) 2009-11-11
HK1077822A1 (en) 2006-02-24
EP2100893A1 (de) 2009-09-16
US9849117B2 (en) 2017-12-26
US9012451B2 (en) 2015-04-21
US7579362B2 (en) 2009-08-25
AU2003260486A1 (en) 2004-03-29
CY1109765T1 (el) 2014-09-10
BR122014026685B1 (pt) 2019-07-09
DK1537104T3 (da) 2010-03-29
US20150183794A1 (en) 2015-07-02
CN1325493C (zh) 2007-07-11
US20120220599A1 (en) 2012-08-30
JP2005539057A (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
DE60330015D1 (de) Aza-bicycloalkylether und deren verwendung als alpha7-nachr agonisten
ATE206122T1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
ATE361924T1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
MY140677A (en) Modified amino acids, pharmaceuticals containing these compounds and method for their production
DE602005008558D1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
NO20053794L (no) N-(1-benzyl-2-oxo-2-(1-piperazinyl) etyl)-1-piperidinkarboksamid-derivater og relaterte forbindelsers bruk som CGRP-antagonister for behandling av hodepine.
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
EA200500342A1 (ru) Гетероциклические замещённые пиперазины для лечения шизофрении
NO20055688L (no) Organiske forbindelser
DE50304569D1 (de) Xanthencarbonsäureester des tropenols und scopins als m3-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
BR0307477A (pt) Compostos quìmicos
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
DK0478446T3 (da) Heterocykliske alkylaminer, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
MX2007010414A (es) Derivados de piridin-2-carboxamida como antagonistas de mglur5.
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
ATE550326T1 (de) Als modulatoren von hdl einsetzbare verbindungen
MXPA05005340A (es) Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.
DK1373218T3 (da) Imidazolylderivater til anvendelse som histamin H3-receptorligander
HUP0401895A2 (hu) Paroxetin N-formil származékai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
DE602004029462D1 (de) Isochinolin-3-carbonsäureamide und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1537104

Country of ref document: EP

EENE Nomination of inventor